Xtandi 40 MG capsule 120S
Ended Awarded
- Contract number
- SPE2DB26FNMNU
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,509
Award facts
- Contract value 100% obligated
- $12,508.77 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $12,508.77 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 120 capsules of XTANDI 40 MG, an oncology medication. The delivery order was awarded on November 10, 2025, with an ultimate completion date of November 12, 2025, and was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This delivery order represents one of numerous pharmaceutical supplies being procured by DLA to support Department of Defense medical operations.
This delivery order is issued under DMS Pharmaceutical Group's recently awarded Indefinite Delivery Contract (IDC) under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying PPV-G GEN V contract, valued at $499,999,999 and extending through December 31, 2036, authorizes DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables to support military healthcare facilities worldwide. DMS Pharmaceutical Group serves as one of multiple regional prime vendor contractors under this strategic sourcing vehicle, positioning the company as a critical supplier within the federal military pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DB26FNMNU?
SPE2DB26FNMNU was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 10, 2025.
How much is contract SPE2DB26FNMNU worth?
The government has obligated $12,509 on SPE2DB26FNMNU.
Is contract SPE2DB26FNMNU an order under another contract?
Yes. SPE2DB26FNMNU is a delivery order under SPE2DB25D9348, an indefinite delivery contract.
Was contract SPE2DB26FNMNU competed?
The extent of competition for SPE2DB26FNMNU was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award